Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by bball67on May 25, 2021 12:59pm
135 Views
Post# 33260473

RE:Reverse Split

RE:Reverse SplitNobody was talking about a reverse split. They were talking about the recent very positive news. This is an attempt to distract and scare. 

A reverse split at the right time will be a positive. I own 1M shares and I am okay with with a reverse split based on the circumstances and timing. Shareholders lose nothing, in fact a NASDAQ listed stock would enable institutional and other shareholders to own the stock. If the stock is at .50, and a 10 for 1 reverse split is completed, I would now own 100,000 shares at $5.00 or a market value of $500,000. I previously owned 1,000,000 shares at .50 or a market value of $500,000. Mathmatically, a reverse split is neutral. I ask the question, wouldn't you rather do the reverse split and own a NASDAQ listed stock. My answer is yes. Let go of the past, there will be new directors and Mr. Goldstein will likely not be on the slate of directors for election. 
<< Previous
Bullboard Posts
Next >>